ALNY - Alnylam Pharmaceuticals Inc
(NaN%)
Sell
Gross Profit was Negative
21%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 12221.33%
Operating Income is Negative but improving
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -174.15%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 4.47
Debt Ratio is 0.7
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Alnylam Pharmaceuticals Inc (ALNY) - https://www.alnylam.com/
Exchange - NASDAQ/NGS (GLOBAL SELECT MARKET)
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - John Maraganore
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.